Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.
Pauline WimbergerJacobus PfistererAndreas du BoisFelix HilpertMarkus KerkmannJalid SehouliSven MahnerNikolaus de GregorioLars HankerFlorian HeitzFrederik MarméLinn WoelberLaura HoltmannGabriele ElserPhilipp Harternull nullPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Although QS-OVAR data showed that the quality of therapy has improved over the years, not all surgical standards were met in nearly 50% of patients. The steady increase in the optimal surgery and chemotherapy collective is an important tool for improvement of prognosis of ovarian cancer patients.
Keyphrases
- quality improvement
- end stage renal disease
- newly diagnosed
- minimally invasive
- ejection fraction
- chronic kidney disease
- prognostic factors
- coronary artery bypass
- stem cells
- squamous cell carcinoma
- machine learning
- electronic health record
- patient reported outcomes
- rectal cancer
- percutaneous coronary intervention
- atrial fibrillation
- replacement therapy